I have a hunch that the mouse MASH results…call it October, result in a partnership and cash infusion, likely higher prices…Cytodyn while not cash-rich can float a bit and erect their two priority studies on HIV Inflammation and MSS CRC. Those results will in turn likely attract interest among BP and potential partnership. Maybe the die is cast and we’ve had our last raise but if not I suspect any further raise will be at much higher prices, fewer shares.